Earlier today, Moderna reported financial results and provided business updates for the third quarter of 2025. Members of our executive team sat down to provide more insight into our financial performance and upcoming late-stage pipeline milestones. Watch now:

Today, we reported financial results and provided business updates for the third quarter of 2025. Read more: https://t.co/D2ybxnIvav

We are proud to be recognized on @biospace's Best Places to Work list of large employers for the fifth-year running! 🎉 This list highlights sought-after employers in life sciences based on community votes and ratings, with a focus on culture, career growth and development

Today we announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, our investigational mRNA-based T-cell engager for participants with relapsed or refractory multiple myeloma (RRMM). Read more: https://t.co/xw144wG4KW

We’re proud to be named a @ScienceCareers Top Employer for the 11th consecutive year! 🏆 This recognition reflects our incredible teams across the globe who turn bold ideas into real-world impact—those who push the boundaries of what’s possible with mRNA science, technology and

Today we announced data regarding two of our investigational influenza candidates will be presented at IDWeek 2025, October 19-22, 2025, in Atlanta, GA. Read more: https://t.co/Nu4YFeWI2K

Today we announced that clinical, safety and translational data from our Phase 1/2 study evaluating mRNA-4359 in combination with pembrolizumab in checkpoint inhibitor-resistant/refractory (CPI-R/R) melanoma patients will be presented at the 2025 European Society for Medical

Today we announced that the Moderna Innovation and Technology Centre (MITC) at the Harwell Science and Innovation Campus in Oxfordshire, UK has officially opened. The MITC will now produce British-made mRNA respiratory vaccines for the UK public to support the National Health

Today we announced positive preliminary immunogenicity data for the 2025-2026 formula of mNEXSPIKE® (COVID-19 Vaccine, mRNA), which targets the LP.8.1 variant of SARS-CoV-2 to help prevent COVID-19. Learn more: https://t.co/9V7geryiOy.

Today we announced that the first mRNA vaccines fully manufactured in Canada are being shipped to Canadian provinces and territories. This milestone advances Canada’s domestic vaccine production capacity and strengthens national health security. Read more:

Today we announced positive preliminary immunogenicity data for the 2025-2026 formula of Spikevax®, which targets the LP.8.1 variant of SARS-CoV-2 to help prevent COVID-19. Learn more: https://t.co/xIyjvDpL48.

We are immensely proud of the role we played in the historic achievements of Operation Warp Speed. COVID-19 vaccines helped end the pandemic, re-open economies and save millions of lives. mRNA, the same technology that helped turn the tide of a global pandemic, is now paving the

Today we announced that five abstracts on our investigational mRNA therapeutics for rare diseases have been accepted for presentation at the 2025 International Congress of Inborn Errors of Metabolism (ICIEM), which will be held September 2-6, 2025, in Kyoto, Japan. Read more:

👋💉 This week, Moderna employees hand-delivered the first shipment of our COVID-19 vaccines to a local pharmacy. We’re grateful to the pharmacies, healthcare professionals and partners who make vaccination possible in our communities.

Today we announced that the U.S. FDA has approved the supplemental Biologics License Applications for the 2025-2026 formulas for Spikevax® and mNEXSPIKE®, targeting the LP.8.1 variant of SARS-CoV-2 to help prevent COVID-19. Read more: https://t.co/uM20Qksf9Y

Today we announced that Health Canada has authorized our updated COVID-19 mRNA vaccine, Spikevax®, targeting the SARS-CoV-2 LP.8.1 variant, for individuals aged six months and older. We are on track to deliver the updated vaccine in time for the 2025-2026 vaccination season.

Earlier today, Moderna reported financial results and provided business updates for the second quarter of 2025. Members of our executive team sat down to provide more insight into our financial performance and upcoming late-stage pipeline milestones. Watch now:

Today, we reported financial results and provided business updates for the second quarter of 2025. Read more: https://t.co/nZMmhIRekU

Today we announced that the UK Court of Appeal has upheld the validity of our EP’949 patent. Read more: https://t.co/ICzz46X0Bo

Today we announced that the European Commission has granted marketing authorization for the updated formulation of our COVID-19 vaccine Spikevax®, targeting the SARS-CoV-2 variant LP.8.1, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals six months